The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

United Therapeutics Stock Surges 12.5% on Positive TETON-1 Study Results for Tyvaso

Key Facts

1The TETON-1 pivotal study evaluating Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint.

2The study demonstrated superiority over placebo in absolute forced vital capacity (FVC) by 130.1 mL.

3TETON-1 results exceeded the treatment effect observed in the previous TETON-2 study.

7 days ago

Create Free Account

Version History

1 additional source confirmed this story

Version 17 days ago

What changed: Added the 12.5% stock price surge and confirmed the TETON-1 study as a Phase III trial paving the way for an FDA filing.

United Therapeutics (UTHR) stock surged by 12.5% following the announcement of successful results from its TETON-1 study for nebulized Tyvaso. The company confirmed that TETON-1 was a Phase III trial, effectively paving the way for a potential regulatory filing with the FDA. The study met its primary efficacy endpoint in treating patients with idiopathic pulmonary fibrosis (IPF), a chronic lung disease. Data revealed a significant improvement in absolute forced vital capacity (FVC) by 130.1 mL compared to the placebo group. Notably, these Phase III results exceeded the treatment effects observed in the previous TETON-2 study. Analysts view this clinical success and the subsequent market reaction as a major fundamental catalyst for the company’s growth in the biotech sector.